FindTrial
Sign In

Do we really need moderate to high dose aspirin in treatment of Kawasaki disease ?

An Observational Study On Use Of Low Dose Aspirin at Treatment Initiation in Kawasaki disease - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/06/068247
Enrollment
83
Registered
2024-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M303- Mucocutaneous lymph node syndrome[Kawasaki]

Interventions

Intervention1: NIL: It is an observational study.

Sponsors

INSTITUTE OF CHILD HEALTH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with KD diagnosed as per AHA 2017 guidelines and receiving low dose aspirin @5mg/kg

Exclusion criteria

Exclusion criteria: Patient receiving high or moderate dose aspirin more than 30mg/kg or infliximab or steroids .

Design outcomes

Primary

MeasureTime frame
Defervescence of fever and reduction of inflammatory markersTimepoint: 48 hours—

Secondary

MeasureTime frame
Coronary artery aneurysmTimepoint: At diagnosis, 2 weeks, 4-6 weeks, 6months—

Countries

India

Contacts

Public ContactAISHIK MUKHERJEE

INSTITUTE OF CHILD HEALTH

mailme.priyankar@gmail.com9831061736

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026